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Objective: The worldwide prevalence of congenital rubella syndrome has drastically decreased after the
uptake of vaccine to prevent the infection. However, outbreaks have occurred in some countries due to
their own vaccination policies, and this phenomenon has not yet been investigated in Taiwan. Our study
aims to ﬁll this gap.
Materials and Methods: We constructed an analytical database containing 10,824 pregnant women at the
Taipei City Hospital, Taipei, Taiwan from January 2004 to July 2012. They were categorized into ﬁve birth
cohorts according to the different vaccination programs in Taiwan: those born before 1971; those born
between September 1971 and August 1976; between September 1976 and August 1979; between
September 1979 and August 1985; and between September 1985 and August 1990. Differences of the
seronegative rate and titers were compared using the Chi-square and KruskaleWallis tests among the
ﬁve cohorts.
Results: The seronegative rates for the ﬁve cohorts were 15.00%, 4.07%, 2.88%, 4.21%, and 10.98%,
respectively, and were statistically signiﬁcant different (p < 0.001). The ﬁrst and ﬁfth cohorts were higher
than the average of seronegativity (5%). The mean of log transformed titers were 3.69 IU/mL, 4.22 IU/mL,
4.22 IU/mL, 4.05 IU/mL, and 3.44 IU/mL, which were statistically signiﬁcant different (p < 0.001). Our
study also found that the equivocal rates (7.58%) were the highest in the cohort born between September
1985 and August 1990, among those who had been vaccinated. Our study showed that women younger
than 27 years had a lower geometric mean titer of antibody titer than the average (60.60 IU/mL).
Conclusion: The previous vaccination policy in Taiwan has created a susceptibility window for rubella
and congenital rubella syndrome over the past decades. We recommend having the antibody test before
pregnancy for women born between September 1985 and August 1990, and implement a catch-up
vaccine for those who were either seronegative or equivocal to prevent reinfection during their child-
bearing period.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Rubella, also known as German measles, is an acute, contagious,
mild viral infection, which unfortunately has serious consequences
for pregnant women [1]. It is usually transmitted via the respiratory
tract by aerosol and caused by a single-stranded RNA virus, which
belongs to the Togaviridae family and was ﬁrst isolated from cellotion and Health Education,
t Road, Section 1, Da-An Dis-
.
bstetrics & Gynecology. Publishedculture in 1962. The typical symptoms included low-grade fever,
malaise, lymphadenopathy, arthritis, arthralgia, and a characteristic
rash lasting for about 3 days, with up to 50% of those infected being
asymptomatic [2,3]. In 1941, an Australian ophthalmologist, Nor-
man Gregg, ﬁrst recognized the association between congenital
cataract cases and maternal rubella in 78 cases [4]. When a preg-
nant woman catches rubella, the virus can cross the placenta, infect
the fetus, and lead to devastating consequences such as miscar-
riage, stillbirth, preterm delivery, and single or multiple birth de-
fects such as deafness, glaucoma, cataract, microcephaly, mental
retardation, and heart disease, which is generally referred to as
congenital rubella syndrome (CRS) [5]. The risk of the fetus withby Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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within the ﬁrst trimester, and negligible by 20 weeks. Some cases
could be diagnosed a fewmonths or years after birth due to the late
presentation of the clinical signs of CRS, while most are noted at the
time of delivery [6].
There are three ways to decrease the susceptibility of the rubella
infection: passively acquired antibody from the mother, wild-type
virus infection, and vaccination. Maternal derived immunoglob-
ulin G (IgG) decays exponentially after birth with protection lasting
for 6e15 months [6,7], and even shorter by half in vaccinated
mothers [8]. Naturally acquired rubella antibodies, predominantly
IgG, which appear a few days after primary infection, have more
persistent and two times higher titers than vaccine-induced.
Rubella vaccines are available either in monovalent formulation,
or more commonly in combinations with other vaccines, namely
rubella-containing vaccines (RCVs), such as with vaccines against
measles; measles and mumps (MMR); or measles, mumps, and
varicella. After the rubella vaccination, the high avidity antibody
takes 2 years to reach its peak and then declines signiﬁcantly in the
15e20 years after a single dose of RCV unless in circumstances
where the wild rubella virus was still endemic and natural boosters
were frequent [9,10]. Therefore, the timing of the second rubella
dose is critical to ensure that immunity against rubella is main-
tained in women of childbearing age [11]. In Taiwan, four reported
epidemics occurred, in 1944,1957e1958,1968e1969, and 1977, and
rubella then became endemic [12]. Taiwan's rubella vaccination
program was launched in 1986 with third grade schoolgirls in ju-
nior high school receiving one dose of rubella (RA 27/3) vaccine.
This program was modiﬁed to one dose of MMR (RA 27/3) vaccine
being given to all junior high and elementary school students and
preschool children in1992e1994withhighcoverage rate (~98%) [13].
CRS inTaiwan is currentlya category3 reportabledisease, andrubella
category 2. Suspected cases must be reported to the Centers for
Disease Control, and samplesmust be sent to the Centers for Disease
Control laboratory for conﬁrmation. The number of conﬁrmed
rubella cases has ﬂuctuated yearly from 2 to 60, with 362 in total
during theperiods of 1992and2013,with onlyﬁve cases of CRSbeing
conﬁrmed since 1994, 3 in 2001 andone each in 2007 and 2008. Two
of themwere indigenous cases [14].
According to previous studies in Taiwan, the proportion of
seronegativity among pregnant women is high, ranging from 10% to
30% [15e18]. Among them, those who were born before 1971 had
the highest seronegativity (20.1%), and those who were born after
1971 had a lower rate of around 6e8%. In addition, those who were
born after 1991 had the lowest seronegativity rate (1%) [15,18,19].
Moreover, about 6.5% of pregnant women who had received the
vaccination still did not have any immunity [15]. Although many
studies have suggested that womenwith the seronegative antibody
should have a catch-up vaccination before they were discharged
from the hospital, the revaccination rate was still low, such as
60e70% in Japan, < 20% in the USA, and an even lower rate of
10e20% in Taiwan [15,16,20,21].
Large-scale rubella vaccination over the last decades has dras-
tically reduced, or practically eliminated rubella and CRS in many
developed as well as in some developing countries. Nevertheless,
rubella outbreaks have still occurred recently in several countries,
including China [22], Poland [23], Romania [24], and Japan [25], and
deservemore attention. The most probable reason for this might be
that these countries failed to ensure that adequate protection was
provided at the time of the changes in the rubella vaccination
programs, thereby continuously causing important public health
issues. Furthermore, the low level of protective immunity amongst
women of childbearing age underlines the importance of the
appropriate screening programs for rubella susceptibility. There-
fore, serological surveillance could provide valuable informationwith which to evaluate a nationwide vaccination program [26]. In
Taiwan, no study has, as yet, paid any attention to this issue. It is
likely that the outbreaks of rubella and CRS might have occurred
due to some susceptible women being infected by other sources
such as travelling to endemic regions or overseas visitors. There-
fore, this study aims to use hospital data sets to investigatewhether
the different cohorts have a different seronegativity, and whether
some of them are susceptible to the infection. The ﬁndings from our
study might provide further evidence for Taiwan's public health
authority to take some preventative measures in order to avert any
outbreaks and/or to eliminate CRS in the future.
Materials and methods
Data source
This is a retrospective study. We used four datasets from the
Taipei City hospital, Fuyou Branch, Taipei, Taiwan, including the
rubella antibody test results from the Laboratory Information Sys-
tem, the Pregnancy Risk Assessment Monitory System, the Birth
Registry Databank, as well as the Hospital Information System, and
linked them by their patient identiﬁers to construct an analytical
database containing pregnant women from January 2004 to July
2012. The earliest rubella test record was retained for those women
who hadmore than two records in the databank after linking all the
datasets mentioned above. After excluding the missing values in
nationality (401, 3.09%), foreigners (1036, 7.97%), and those who
were born after August 1990 [vaccinated with 2 doses of MMR (39,
0.30%)], with the total study sample being 10,824. The Ethics Re-
view Board of Taipei City Hospital approved this study protocol (No.
TCHIRB-1030326-E).
Serological tests
Rubella IgG antibodies were determined through an enzyme
immunoassay. The test results for our study sample were all ob-
tained using IMMULITE 2000 (Siemens, Munich, Germany). The
antibody titers were obtained in the IU/mL based on the Interna-
tional Standard for Anti-Rubella (2nd international standard prep-
aration) sera of the World Health Organization, included as the
reference sera by the manufacturer. The lower and upper detection
limits for the rubella virus IgG were 0 IU/mL and 500 IU/mL,
respectively. Currently, an antibody level of > 10 IU/mL is recog-
nized to be protective but < 15 IU/mL has been reported to allow
reinfection [27]. Based on the previous literature and the Interna-
tional Standards, serum IgG levels of 15 IU/mLwere considered to
be seropositive or immune; those of 10e15 IU/mL were considered
to be equivocal, susceptible or weakly positive [28e30];
those < 10 IU/mL were considered to be seronegative or nonim-
mune [31].
Statistical analysis
The women were categorized into ﬁve birth cohorts according
to the history of the rubella vaccination programs in Taiwan. Cohort
1 was born before September 1971 and no rubella vaccination
program was provided during their childhood. Cohort 2 was born
between Septembers 1971 and August 1976, and received one dose
of rubella vaccine when they were 15 years old. Cohort 3a was born
between September 1976 and August 1979, and received one dose
of MMR when they were age 15 years old. Cohort 3b was born
between September 1979 and August 1985, and received one dose
of MMR when they were 7e12 years old. Cohort 3c was born be-
tween September 1985 and August 1990, and received one dose of
MMR when they were 6 years old (Table 1).
Table 1
Vaccine doses and uptake rates under national programs by birth cohorts.
Birth cohort Birth year Vaccination program against rubella in Taiwan RCV total doses Estimated uptake rate of RCVa
Universal administration at the
age of:
Booster campaigns Childbearing-age-women
catch-up vaccinationb
15 mo 5 y 7e12 y 15 y 2001/12e2004/3 1987e2001/6 After 2001/9
1 Prior to 1971 d d d d d Rubella MMR 0þc NA
2 1971/9e1976/8 d d d Rubellad d Rubella MMR 1þc 98%
3a 1976/9e1979/8 d d d MMR d Rubella MMR 1þc NA
3b 1979/9e1985/8 d d MMR d d Rubella MMR 1þc NA
3c 1985/9e1990/8 d MMR d d d Rubella MMR 1þc NA
3d 1990/9e1994/8 MMR d d d MMR d MMR 2þc 90.57%e
4 1994/9e1998/8 MMR d d d MMR d MMR 2þc 96.31%f
Adapted from the document of the Centers for Disease Control, Taiwan [6].
MMR ¼ measlesemumpserubella vaccine; NA ¼ not available; RCV ¼ rubella-containing vaccine.
a Excludes catch-up vaccination.
b Catch-up vaccination is voluntary.
c Doses of voluntary catch-up vaccine.
d Female only.
e 1994e1995.
f 1996e1997.
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quantiﬁcation, which is 0 IU/mL, were assumed to be equivalent to
half of the lower limit of quantiﬁcation (0.02 IU/mL for rubella) [8].
Due to the positive skewness of the raw titers, we used the log-
transformed titer to conduct a statistical test across the ﬁve co-
horts [18]. We ﬁrst conﬁrmed whether the homogeneity
assumption holds for the log-transformed Rubella titers using
Levene's test, and found that heterogeneity existed across the
cohorts; therefore, we chose the nonparametric method, the
KruskaleWallis test, to compare the differences in the titers
among the ﬁve cohorts. The geometric mean titer (GMT) was
calculated using the log-transformed values from the individual
titers; the GMT was taken as the antilog of the mean of the
transformed values [32]. We presented seronegative rates, mean
of the log-transformed titers, the GMT, and a 95% conﬁdence in-
terval of the GMT. The participants were categorized by birth co-
horts, age, and the time after vaccination (TAV). The TAV was
calculated as the difference between the test year and the earliest
year of receiving the vaccination. Since there is no speciﬁc test
date, therefore, the age at the test date was calculated in months.
Differences of the seronegative rate among the birth cohorts were
compared using the Chi-square test. Post hoc comparisons were
also used to identify the difference of seronegative rates between
two cohorts. All statistical analyses were conducted using the SAS
version 9.4 software by SAS Institute Inc., Cary, NC, USA.
Results
The mean of the rubella IgG antibody is 105.46 IU/mL with a
standard deviation of 113.61 IU/mL. The minimum and maximum
values were 0.01 IU/mL and 500 IU/mL, respectively. Table 2 shows
that the seronegative rate was relatively higher in Cohort 1 andTable 2
Cohort-speciﬁc seronegative rate and geometric mean titers of rubella in 10,824 women
Cohort n Seronegative rate (%)
(95% CI)
Equivocal ra
(95% CI)
1 1,053 15.00 (12.90e17.31) 2.09 (1.31e
2 3,444 4.07 (3.43e4.78) 2.21 (1.74e
3a 3,094 2.88 (2.32e3.53) 2.36 (1.85e
3b 2,969 4.21 (3.52e5.00) 2.93 (2.35e
3c 264 10.98 (7.48e15.39) 7.58 (4.69e
Total 10,824 5.00 (4.60e5.43) 2.57 (2.28e
CI ¼ conﬁdence interval. GMT ¼ geometric mean titer.Cohort 3c, which were all above the average of all cohorts. How-
ever, since the equivocal rate for Cohort 3c is higher than Cohort 1,
the seropositive rate (not shown in Table 2) is actually slightly
lower than that of Cohort 1. According to the Chi-square test, the
seronegative rate was shown to be statistically signiﬁcant different
across the ﬁve cohorts (p < 0.001). After conducting post hoc
comparisons, Cohort 3c was statistically different from other co-
horts (p < 0.001) except Cohort 1 (p ¼ 0.0943; not shown in the
table). Titers among the ﬁve cohorts were also shown to have
statistically signiﬁcant difference based on the KruskaleWallis test
(p < 0.001).
Figure 1 shows that thosewhowere younger than 27 years had a
lower GMT than the average and had a lower seropositive rate than
the average. For women who were 21 years old, the GMT was the
lowest (24.3 IU/mL) and had the lowest seropositive rate (69.05%).
Within this age group, ~78.57% (n ¼ 33) were from Cohort 3c, ac-
counting for 12.5% of all women in Cohort 3c (n ¼ 264). The
equivocal rates were higher than the average for those who were
age 20e26 years (range, 2.86e7.14%). The peak of the GMToccurred
in women who were age 32 years, which was 70.92 IU/mL. In
addition, those who were aged 36 and over had a lower seroposi-
tive rate as well as GMT than that of the average.
Figure 2 shows the different GMT patterns for Cohort 2 and
Cohort 3 (including Cohorts 3a, 3b, and 3c) based on the TAV. For
both cohorts, the GMT increased and then declined after a number
of years. For Cohort 2, the GMT reached its peak of 90.93 IU/mL at
21 years, and it was 125.47 IU/mL at 14 years for Cohort 3. The level
of GMT remained stable after it declined to approximately 49 IU/mL.
However, it has been noted that the highest level of the GMT for
Cohort 2 had never exceeded the highest level of the GMT for Cohort
3. The increasing rate of the GMT for Cohort 3 was higher than that
of Cohort 2, but declined more rapidly than that of Cohort 2..
te (%) Mean of ln (titers of rubella)
(95% CI)
GMT (IU/mL)
(95% CI)
3.15) 3.69 (3.56e3.82) 68.30 (65.50e71.23)
2.75) 4.22 (4.18e4.27) 68.24 (65.79e70.78)
2.96) 4.22 (4.19e4.26) 57.26 (55.11e59.50)
3.60) 4.05 (4.01e4.09) 31.33 (27.19e36.10)
11.46) 3.44 (3.30e3.59) 40.04 (35.23e45.51)
2.88) 4.10 (4.08e4.13) 60.60 (59.16e62.08)
Figure 1. Age-speciﬁc seronegative rate, geometric mean titers, and the conﬁdence limit of rubella in 10,824 women.
C.-L. Lin et al. / Taiwanese Journal of Obstetrics & Gynecology 55 (2016) 368e373 371Discussion
This study used a large sample from the Taipei City hospital,
Fuyou Branch, containing 10,824 pregnant women from 2004 to
2012. Our results showed that both the seronegative rate and the
GMT were statistically different across the ﬁve birth cohorts. In
addition, women born between September 1985 and August 1990
(Cohort 3c) had a higher seronegative rate as well as equivocal rate.
This group was exposed to a higher risk of being affected. It is
possible that such a susceptibility window for this cohort is due to
the vaccination policy implemented during recent decades.
In our data, women in Cohort 1 did not receive any RCV and they
acquired immunity through natural infection [18]. For Cohort 2 and
Cohort 3a, the women received one dose of rubella and MMR
vaccination, respectively, when theywere 15 years old. Our ﬁndings
showed that the low seronegative rate for these two cohorts were
consistent with Wang et al's [18] study, which might be partly due
to the vaccination, and partly due to naturally-acquired immunity.
Although Cohorts 3b and 3c both received only one dose of the
MMR vaccine when they were 7e12 years old and 5 years old in anFigure 2. Time after vaccination-speciﬁc geometric mean titers of rubella in 10,824
women. TAV ¼ time after vaccination.environment where there was little chance for natural infection,
the seronegative rate for Cohort 3b was still low, while it was sur-
prisingly high for Cohort 3c. This ﬁnding is different from that of
Wang et al [18] where the seronegative rate for the cohort born
between 1982 and 1985 was 7.6% and 3.2% for those born between
1987 and 1989. However, our ﬁndings support those of Lin et al
[15,31] and Davidkin et al [10] that antibody titers declined with
time. The possible explanation was that the TAV was shorter for
Cohort 3b, and even though the titers were decreasing, they were
not below the threshold of seronegativity. For Cohort 3c, due to the
longer TAV, the rubella antibody titers had declined to lower than
the seronegativity level at a larger proportion.
Galazka [33] showed that, as long as the seronegative rate
among women was 2e3%, then it was very likely that an outbreak
would occur. Therefore, many previous studies suggested that
women with a seronegative antibody level could have a catch-up
vaccine before being discharged from hospital after delivering
their babies [15,16,31,34e36]. Davidkin et al [28] showed that the
titers were much higher for those who had the lowest antibody
levels after revaccination than that of women who were naturally
immunized or those who received vaccines. In Taiwan, the rubella
IgG test is routine for prenatal care with high implementation, but
the rate of the catch-up MMR vaccine, as per the government's
recommendation, is very limited [15]. Moreover, the screening
program does not reduce mother-to-baby transmission and has no
advantage for the current pregnancy [37]. Yamada et al [36,38]
further suggested that in order to prevent CRS, for those who did
not have protective level of antibody, the government should adjust
its vaccination policy, especially for the younger population
regardless of their sex. A good model is the Blessing your Pregnancy
program launched by the Taipei City government, which has pro-
vided free rubella IgG tests for those married couples before their
pregnancy and free catch-up MMR vaccine if seronegative. Unfor-
tunately, it has not been a nationwide campaign.
Our study found that the GMT for these two cohorts did reveal
different patterns in terms of the TAV. For Cohort 2, it took
~21 years for the GMT to achieve the maximum value, and the
waning rate was slower; by contrast, the increasing rate of the
GMT for Cohort 3 was much higher than that of Cohort 2 and it
took approximately 14 years to achieve the maximum value with a
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rubella and the MMR vaccine was different.
Skendzel [30] and the US Centers for Disease Control have
proposed that the cutoff points for seronegativity should be
reduced from 15 IU/mL to 10 IU/mL since those whose antibodies
were above this level could be prevented from becoming infected.
However, there were some cases with titers above 10 IU/mL that
were still previously infected. In our study, we deﬁned 10e15 IU/mL
as equivocal to suggest that those who fall within this level might
receive more attention as they could have a higher chance of
becoming infected years later. It is suggested that future research
should focus on how to establish a standard for the immunity level
of rubella. In addition, since our study only focused onwomenwith
one dose of MMR, it is suggested that future research should
analyze those with two doses and investigate the changes of titers
across the TAV.
Our study had some limitations. One is that the sample taken is
only from the Taipei City Hospital and may not represent the whole
picture nationwide. Second, we were not able to conﬁrm as to
whether the women had received a catch-up vaccine after delivery;
however, since the catch-up rate was very low, we expected that
this limitation would not affect our results in any signiﬁcant way.
Third, we were not able to assure that immunity is totally from the
vaccination, especially for Cohort 2 and Cohort 3a, who experi-
enced an outbreak of rubella in Taiwan.
Our study suggested that for those whose antibody is seroneg-
ative or equivocal, they should all have a catch-up vaccine after the
birth of their baby. In addition, it is highly recommended that the
government should stimulate rubella IgG tests for Cohort 3c, and
catch-up vaccine for them when the test results were either sero-
negative or equivocal as the titers for those who fell within the
equivocal range would keep decreasing. Moreover, it is possible
that the antibody will fall below 10 IU/mL when they were preg-
nant under the condition that most of the women delayed child-
bearing. Finally, comparing the patterns of the GMT for Cohort 2
and Cohort 3 across the TAV, we found that only one dose of vaccine
could not protect all women of childbearing age. It is suggested that
the best time for the second dose of MMR is probably 14 years after
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